Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery

Inclusion Criteria: * Histologically confirmed biliary tract carcinoma * Surgically unresectable disease * Meets any of the following criteria for biliary cancers only: * Received ≤ 1 prior systemic anticancer therapy, including chemoembolization * Received prior cryotherapy, radiofrequency ablation, ethanol injection, transarterial chemoembolization, or photodynamic therapy AND meets the following criteria: * More than 6 weeks have elapsed since any of the prior therapy described above * Indicator lesion(s) must be outside the area of prior treatment OR must demonstrate clear evidence of disease progression if the only indicator lesion is inside the prior treatment area * Indicator lesion must have clearly distinct edges on CT scan * Prior radiotherapy with or without the use of a fluoropyrimidine as a radiosensitizer is allowed, provided more than 12 weeks have elapsed since treatment * Fresh or paraffin-embedded tissue from tumor blocks must be available for review * Measurable disease, defined as ≥ 1 unidimensionally measurable lesion \> 20 mm by conventional techniques or \> 10 mm by spiral CT scan * No known brain metastases * Life expectancy \> 12 weeks * ECOG performance status (PS) 0-1 or Karnofsky PS 70-100% * ANC ≥ 1,500/μL * Platelet count ≥ 75,000/μL * Total bilirubin ≤ 2 times upper limit of normal(ULN) * AST or ALT ≤ 3 times ULN * Serum albumin ≥ 2.5 mg/dL * INR ≤ 1.5 (not receiving anticoagulation therapy) * Creatinine normal or creatinine clearance ≥ 60 mL/min * Not pregnant or nursing * Negative pregnancy test * Fertile women must use effective contraception during and for four weeks after the last dose of AZD6244 * Fertile men must use effective contraception during and for 16 weeks after the last dose of AZD6244 * No significant traumatic injury within the past 3 weeks * No uncontrolled symptoms consistent with encephalopathy * No history of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD6244 or its excipient, Captisol® * No QTc interval \> 500 msecs or other factors that increase the risk of QT prolongation or arrhythmic events (e.g., hypokalemia or family history of long QT interval syndrome), including NYHA class III-IV heart failure * No other malignancy within the past 3 years, except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix * No refractory nausea and vomiting, chronic gastrointestinal disease (e.g., inflammatory bowel disease), or significant bowel resection that would preclude adequate absorption * No uncontrolled concurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situation that would limit compliance with study requirements * No malignant hypertension within the past year * No prior sorafenib or MEK inhibitors * More than 4 weeks since prior chemotherapy, biologic therapy, or immunotherapy (6 weeks for nitrosoureas or mitomycin C) and recovered to ≤ grade 1 adverse events * No major surgery within the past 3 weeks * No other concurrent investigational agents * No concurrent requirement for medication that can prolong the QT interval * No concurrent combination antiretroviral therapy for HIV-positive patients * No concurrent consumption of grapefruit or grapefruit juice